Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | What to expect from TCT 2021?

Per Ljungman • 5 Feb 2021
TCT 2021
General

Per Ljungman, MD, PhD, Karolinska Institute, Stockholm, Sweden, discusses what to expect from the upcoming Transplantation & Cellular Therapy (TCT) 2021 Meeting. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Per Ljungman

Drug-drug interaction management with the novel anti-CMV agents letermovir and maribavir
1:00
Drug-drug interaction management with the novel anti-CMV agents letermovir and maribavir
Per Ljungman • 1 Apr 2025
Does CMV remain a concern when performing transplantation in 2025?
1:00
Does CMV remain a concern when performing transplantation in 2025?
Per Ljungman • 1 Apr 2025
The updated ECIL guidelines for the management of CMV
1:15
The updated ECIL guidelines for the management of CMV
Per Ljungman • 1 Apr 2025
Stem cell transplantation & cellular therapy during COVID-19 in Europe
5:37
Stem cell transplantation & cellular therapy during COVID-19 in Europe
Per Ljungman • 5 Feb 2021

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
1:46
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
Michael Jain • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals